Tags

Type your tag names separated by a space and hit enter

Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness.
Nutr Rev 2016; 74(7):455-68NR

Abstract

Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. Clinically meaningful treatment goals were defined as an FPG of ≤7.2 mmol/dL, a decline in HbA1c to ≤7%, or a decrease of ≥0.5% in HbA1c. In only a few randomized controlled trials did FPG (5 of 20), HbA1c (3 of 14), or both (1 of 14) reach the treatment goals with chromium supplementation. HbA1c declined by ≥0.5% in 5 of 14 studies. On the basis of the low strength of existing evidence, chromium supplements have limited effectiveness, and there is little rationale to recommend their use for glycemic control in patients with existing T2DM. Future meta-analyses should include only high-quality studies with similar forms of chromium and comparable inclusion/exclusion criteria to provide scientifically sound recommendations for clinicians.

Authors+Show Affiliations

R.B. Costello, J.T. Dwyer, and R.L. Bailey are with the Office of Dietary Supplements, National Institutes of Health, Bethesda, Maryland, USA. J.T. Dwyer is with the School of Medicine and Friedman School of Nutrition Science and Policy, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA. R.L. Bailey is with the Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA. costellb@od.nih.gov.R.B. Costello, J.T. Dwyer, and R.L. Bailey are with the Office of Dietary Supplements, National Institutes of Health, Bethesda, Maryland, USA. J.T. Dwyer is with the School of Medicine and Friedman School of Nutrition Science and Policy, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA. R.L. Bailey is with the Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.R.B. Costello, J.T. Dwyer, and R.L. Bailey are with the Office of Dietary Supplements, National Institutes of Health, Bethesda, Maryland, USA. J.T. Dwyer is with the School of Medicine and Friedman School of Nutrition Science and Policy, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, USA. R.L. Bailey is with the Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27261273

Citation

Costello, Rebecca B., et al. "Chromium Supplements for Glycemic Control in Type 2 Diabetes: Limited Evidence of Effectiveness." Nutrition Reviews, vol. 74, no. 7, 2016, pp. 455-68.
Costello RB, Dwyer JT, Bailey RL. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutr Rev. 2016;74(7):455-68.
Costello, R. B., Dwyer, J. T., & Bailey, R. L. (2016). Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutrition Reviews, 74(7), pp. 455-68. doi:10.1093/nutrit/nuw011.
Costello RB, Dwyer JT, Bailey RL. Chromium Supplements for Glycemic Control in Type 2 Diabetes: Limited Evidence of Effectiveness. Nutr Rev. 2016;74(7):455-68. PubMed PMID: 27261273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. AU - Costello,Rebecca B, AU - Dwyer,Johanna T, AU - Bailey,Regan L, Y1 - 2016/05/31/ PY - 2016/6/5/entrez PY - 2016/6/5/pubmed PY - 2017/8/31/medline KW - chromium KW - fasting plasma glucose KW - hemoglobin A1c KW - type 2 diabetes mellitus. SP - 455 EP - 68 JF - Nutrition reviews JO - Nutr. Rev. VL - 74 IS - 7 N2 - Some adults with type 2 diabetes mellitus (T2DM) believe that chromium-containing supplements will help control their disease, but the evidence is mixed. This narrative review examines the efficacy of chromium supplements for improving glycemic control as measured by decreases in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c). Using systematic search criteria, 20 randomized controlled trials of chromium supplementation in T2DM patients were identified. Clinically meaningful treatment goals were defined as an FPG of ≤7.2 mmol/dL, a decline in HbA1c to ≤7%, or a decrease of ≥0.5% in HbA1c. In only a few randomized controlled trials did FPG (5 of 20), HbA1c (3 of 14), or both (1 of 14) reach the treatment goals with chromium supplementation. HbA1c declined by ≥0.5% in 5 of 14 studies. On the basis of the low strength of existing evidence, chromium supplements have limited effectiveness, and there is little rationale to recommend their use for glycemic control in patients with existing T2DM. Future meta-analyses should include only high-quality studies with similar forms of chromium and comparable inclusion/exclusion criteria to provide scientifically sound recommendations for clinicians. SN - 1753-4887 UR - https://www.unboundmedicine.com/medline/citation/27261273/Chromium_supplements_for_glycemic_control_in_type_2_diabetes:_limited_evidence_of_effectiveness_ L2 - https://academic.oup.com/nutritionreviews/article-lookup/doi/10.1093/nutrit/nuw011 DB - PRIME DP - Unbound Medicine ER -